Sweet Dreams

. . . The much-anticipated launch of LUNESTA(TM), an insomnia treatment, by Sepracor (Nasdaq: SEPR) is expected in the first few weeks of April. So far, more than 40,000 retail pharmacies have already placed orders with wholesalers. Why all the anticipation? LUNESTA is the first and only sleep medication approved for long- term use. It has proven effective in long-term, continuous treatment, with a lack of significant rebound when therapy is discontinued. In addition, clinical studies showed no measurable next-day residual effects in most patients. Insomnia is an enormous market with an estimated 100 million adult Americans suffering from either chronic or occasional insomnia. In the past decade, Ambien has been the blockbuster insomnia drug, however, it is only recommended for short-term use.

From: www.InvestingIN.com/biotech